In an article by Sue Barnes, RN, CIC (the former national program leader for infection prevention at Kaiser Permanente) on Infection Control Today, she discusses nasal decolonization and hospital acquired infection prevention and lists out applications and evidence. Nozin® Nasal Sanitizer® antiseptic was one of the products suggested to be considered for nasal decolonization as antimicrobial resistance is not an issue with Nozin as can occur with mupirocin.
For facilities focused on effective infection control, lower cost screen and treat programs, and antibiotic stewardship, nasal decolonizing antiseptics are an alternative or may easily be used in conjunction with their current protocols. Much of the information on efficacy is related to mupirocin as the agent most used historically; however, the rapid action and convenience of alternatives like Nozin® Nasal Sanitizer® antiseptic make them viable with advantages in hospital and high risk environments.
Healthcare-associated infections (HAIs) affect more than 2 million patients annually and cost over $4.5 billion.1 Infection prevention bundles are increasingly being used that include nasal decolonization, and evidence supporting its effectiveness is growing.”
“Although mupirocin (trade names including Bactroban, Centany) is commonly used for nasal decolonization, it may be prudent to consider new nasal antiseptics with which antimicrobial resistance is not an issue [trade names including Nozin (alcohol) and 3M and Clorox (iodine)].”
“The rapid action and convenience of these alternatives to antibiotic use may also provide a wider range of opportunities to reduce the infection risk that nasal carriage brings to the healthcare environment.”
“The role of nasal bacteria in HAI development and transmission and the efficacy of nasal decolonization to reduce infection has been established… in the face of widespread antimicrobial resistance, judicious use of antibiotics has never been more important. Other concerns with mupirocin include that it is slow to reach full effect, generally requiring a five-day, twice-daily application. Patient compliance with this self-application protocol is a common challenge.” The newer nasal decolonizing antiseptics permit just-in-time application by healthcare providers rather than patients, fast broad spectrum effect, and little or no resistance potential. Read the full article
For further information about Nozin Nasal Sanitizer:
The Medical University of South Carolina initiated a clinical study that incorporated Nozin Nasal Sanitizer (see link at clinicaltrials.gov). The study is now complete and the results are published in the American Journal of Infection Control.
Read our Important nasal decolonization white paper: “Emerging Strategies on Achieving Nasal Decolonization for Reducing Hospital Acquired Infections” by Phenelle Segal, RN, CIC. Free download.